Novo Nordisk A/S (NVO)
45.60
-0.66
(-1.42%)
USD |
NYSE |
Aug 28, 16:00
45.57
-0.04
(-0.08%)
After-Hours: 20:00
Novo Nordisk Cash from Operations (Quarterly) : 8.364B for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.364B |
| March 31, 2026 | 3.665B |
| December 31, 2025 | 1.243B |
| September 30, 2025 | 7.317B |
| June 30, 2025 | 3.193B |
| March 31, 2025 | 6.325B |
| December 31, 2024 | 1.877B |
| September 30, 2024 | 6.446B |
| June 30, 2024 | 7.310B |
| March 31, 2024 | 2.084B |
| December 31, 2023 | 1.387B |
| September 30, 2023 | 5.942B |
| June 30, 2023 | 4.176B |
| March 31, 2023 | 4.298B |
| December 31, 2022 | 834.40M |
| September 30, 2022 | 3.330B |
| June 30, 2022 | 3.424B |
| March 31, 2022 | 3.556B |
| December 31, 2021 | -604.25M |
| September 30, 2021 | 3.429B |
| June 30, 2021 | 4.093B |
| March 31, 2021 | 1.823B |
| December 31, 2020 | 154.46M |
| September 30, 2020 | 2.734B |
| June 30, 2020 | 3.581B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.478B |
| December 31, 2019 | 742.37M |
| September 30, 2019 | 2.500B |
| June 30, 2019 | 2.267B |
| March 31, 2019 | 1.506B |
| December 31, 2018 | 1.107B |
| September 30, 2018 | 1.802B |
| June 30, 2018 | 2.535B |
| March 31, 2018 | 1.622B |
| December 31, 2017 | 1.015B |
| September 30, 2017 | 1.993B |
| June 30, 2017 | 1.502B |
| March 31, 2017 | 1.736B |
| December 31, 2016 | 1.625B |
| September 30, 2016 | 2.262B |
| June 30, 2016 | 2.186B |
| March 31, 2016 | 1.108B |
| December 31, 2015 | 1.443B |
| September 30, 2015 | 1.845B |
| June 30, 2015 | 1.785B |
| March 31, 2015 | 619.60M |
| December 31, 2014 | 1.204B |
| September 30, 2014 | 2.195B |
| June 30, 2014 | 1.493B |
| March 31, 2014 | 747.10M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AstraZeneca PLC | 3.420B |
| Johnson & Johnson | 8.616B |
| Eli Lilly & Co. | 10.69B |
| Merck & Co., Inc. | 5.37B |
| Novartis AG | 5.888B |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.009B |
| Cash from Financing (Quarterly) | -2.708B |
| Free Cash Flow | 7.517B |
| Free Cash Flow Per Share (Quarterly) | 1.434 |
| Free Cash Flow to Equity (Quarterly) | 7.500B |
| Free Cash Flow to Firm (Quarterly) | 6.544B |
| Free Cash Flow Yield | 3.71% |